Compass Pathway's fourth U.S. patent covers its Form A hydrate psilocybin, and is the first patent for this formulation.
Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton
Field Trip is adding three new clinics to its network, with two of the three already open and the third opening imminently.
First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial
Small Pharma commences enrolling patients for its Phase IIa DMT-based clinical trial aimed at treating Major Depressive Disorder.
Real World Evidence (RWE) Drug Development: A Faster/Cheaper Route For Psychedelics
Drug development through the formal clinical trials process is slow and expensive. Real World Evidence (RWE) drug development is fast and cheap. Have we got your attention yet?
Levitee Labs Announces Agreement with Adracare, a WELL Health Company, to Support Individuals with Addiction and Mental Health Conditions
Levitee Labs announces a partnership with Adracare Inc., a subsidiary of Well Health Technologies (WELL), to build out a digital therapeutics platform.
Psychedelic Medicine: The Only Hope In Solving The Mental Health LABOR CRISIS
The "crippling labor shortages" plaguing the U.S. economy are directly attributable to the Mental Health Crisis. Psychedelic medicine is the only answer.
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome
PharmaTher receives its second FDA orphan drug designation for a ketamine-based therapy.
MindMed Joins Clinical Trials Transformation Initiative
MindMed joins the Clinical Trials Transformation Initiative, a forward-looking healthcare association that develops/promotes new health therapies.
Novamind Granted DEA Licenses for Psilocybin Research
Novamind's new DEA licenses open up opportunities to host formal clinical trials.
Cybin Files an International Patent Application Covering Psychedelic Delivery Methods
Cybin files a new patent application in support of the development of drug candidate CYB004.
Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations
Psychedelic stocks today are cash-rich with extremely attractive valuations. Blue-chip stocks sit with record debt levels and grossly inflated valuations. Advantage: psychedelic stocks.
Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities
Numinus announces expansion of its psychedelics research facility and an application to Health Canada for a second Dealer's License.
